{"id":"bio101","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal disorders"},{"rate":"null","effect":"Musculoskeletal disorders"}]},"_chembl":{"chemblId":"CHEMBL224128","moleculeType":"Small molecule","molecularWeight":"480.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BIO101 works by inhibiting the SARM1 protein, which is involved in the activation of the NAD+ breakdown pathway. This leads to a decrease in the production of toxic aldehydes that cause mitochondrial dysfunction. By preventing mitochondrial dysfunction, BIO101 aims to slow down or halt the progression of various diseases.","oneSentence":"BIO101 is a small molecule targeting the SARM1 protein to prevent mitochondrial dysfunction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:11:51.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":"Muscle Wasting, Obesity & Overweight, Obesity","enrollment":164},{"nctId":"NCT03452488","phase":"PHASE2","title":"A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)","status":"COMPLETED","sponsor":"Biophytis","startDate":"2017-02-07","conditions":"Sarcopenia, Gait Disorders in Old Age, Muscle Weakness","enrollment":233},{"nctId":"NCT04472728","phase":"PHASE2, PHASE3","title":"Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients","status":"TERMINATED","sponsor":"Biophytis","startDate":"2020-08-26","conditions":"Covid-19, SARS-CoV2","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sarconeos (BIO101)","20 hydroxyecdysone (20E)"],"phase":"phase_2","status":"active","brandName":"BIO101","genericName":"BIO101","companyName":"Biophytis","companyId":"biophytis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIO101 is a small molecule targeting the SARM1 protein to prevent mitochondrial dysfunction. Used for Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}